ProCE Banner Events

Share

Are You Applying the Latest Guidelines for Multiple Myeloma? Experts Discuss Equitable, Evidence-Based Care

Join us for this case-based, interactive, CME/CE-certified live webinar featuring expert perspectives on treatment for patients with newly diagnosed and relapsed/refractory multiple myeloma. Be sure to bring your questions for the live Q&A session with the expert panel.

Who Should Attend

This program is intended for hematologists, oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma.

Time and location

Tuesday, January 21, 2025

6:00 PM - 7:30 PM Eastern Time (ET)

Virtual

Faculty
Jens Hillengass, MD, PhD

Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Carol Ann Huff, MD

Medical Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology and Medicine
Multiple Myeloma Program
Johns Hopkins University School of Medicine
Baltimore, Maryland

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Agenda

Overview and Unmet Needs in MM

Ensuring Equitable Care for Minority Patients With MM

When Do You Consider Therapy for Patients With Smoldering MM?

Optimal Treatment for Newly Diagnosed MM

Updates on New Treatment Options for R/R MM

Closing Remarks: The New Algorithm for MM Treatment

Question and Answer Session

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with multiple myeloma. 

Target Audience
This program is intended for hematologists, oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Initiate timely systemic treatment for appropriate patients based on risk assessment and the latest multiple myeloma diagnostic and staging criteria
  • Develop individualized treatment strategies for patients with newly diagnosed multiple myeloma through consideration of the available clinical data as well as NCCN guidelines, risk assessment, comorbidities, and patient age/fitness and preferences
  • Select optimal therapies for patients with heavily pretreated relapsed/refractory multiple myeloma based on individual patient and disease characteristics, as well as NCCN guideline recommendations, and response to and tolerance of previous therapies
  • Appraise the efficacy and safety evidence of novel therapeutics and emerging combination regimens for patients with multiple myeloma
  • Identify patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on key ongoing clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: TBD

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

This educational activity is supported by an independent medical education grant from GSK and an educational grant from Sanofi.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.